“ I was actually at #ECNP2024 yesterday, where J&J presented a bit more esketamine data (this time as monotherapy) during the new drugs panel. Honestly, it wasn’t bad, though it was right after this phase 3 evenamide trial that knocked my socks off and had me texting a friend with excitement (don’t sleep on that drug - it’ll change psychosis care in the next 10 years if the second p3 is anything close to the first).”
- Zack Williams, PhD